Unichem Labs gets USFDA nod for Aripiprazole Tablets

Published On 2021-12-03 07:35 GMT   |   Update On 2021-12-03 07:35 GMT

Mumbai: Unichem Laboratories Limited has recently announced that the company has received approval from the United States Food and Drug Administration (USFDA) for its schizophrenia pill Aripiprazole Tablets.

Aripiraprazole tablets are indicated for schizophrenia and irritability associated with autistic disorders.

"Unichem Laboratories has received ANDA approval for its Aripiprazole Tablets USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg from the United States Food and Drug Administration to market a generic version of Abilify Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Otsuka Pharmaceutical Company Ltd," the company said in a statement.

The product will be commercialised from Unichem's Ghaziabad plant.

Read also: Unichem Labs gets USFDA nod for Metformin Hydrochloride ER Tablets

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. 

Read also: Unichem Labs diabetes drug Sitagliptin gets USFDA approval

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News